Key result
Post-PCI aspirin continuation shows no increased bleeding risk during or after cataract surgery.
Why the study?
The safety and bleeding risk of continuing long-term aspirin use during cataract phacoemulsification after PCI remain controversial and underreported.
Does continuing long-term aspirin after PCI increase bleeding complications during cataract phacoemulsification compared to patients on aspirin for secondary prevention or those not taking antithrombotics?
Observational (n=524)
Does continuing long-term aspirin after PCI increase bleeding complications during cataract phacoemulsification compared to patients on aspirin for secondary prevention or those not taking antithrombotics?
p-value: p=> 0.05
Continuing long-term aspirin after PCI does not significantly increase the risk of bleeding complications during cataract phacoemulsification, supporting the safety of the procedure without stopping antithrombotic drugs.
May support continuing aspirin perioperatively post-PCI; leaves open need for randomized confirmation.
PURPOSE: It is a controversial issue whether to discontinue antithrombotic drugs during the perioperative period of cataract surgery. There are few reports on the safety of long-term aspirin use after percutaneous coronary intervention (PCI). In this study, we evaluated the bleeding risk and surgical safety of cataract phacoemulsification in patients who took aspirin for a long time after PCI, so as to provide relevant evidence for this problem. METHODS: Retrospective analysis of the cases of cataract surgery. The incidence of bleeding-related complications in patients without history of antithrombotic drugs, patients without cardiac surgery who had taken aspirin at least 1 year for secondary prevention, and patients with long-term aspirin use 1 year after PCI were compared. RESULTS: A total of 81 patients (81 eyes, n = 81) after PCI (≥1 year) were collected. One hundred fifty-eight patients (158 eyes, n = 158) without cardiac surgery in the aspirin group and 285 patients (285 eyes, n = 285) without history of antithrombotic drugs were collected. Subconjunctival hemorrhage and hyphema occurred in all three groups, but the difference was not statistically significant ( P > 0.05). No other serious bleeding-related complications occurred in the three groups during the operation, 1 day and 1 week after operation. CONCLUSION: No matter intraoperative or postoperative, bleeding-related complications are rare in patients after PCI, which demonstrates a certain degree of surgical safety and can prove the safety of cataract surgery without stopping antithrombotic drugs.
No takes yet. Share an insight, caveat, or question.
Zicheng et al. (2023) conducted an observational in Cataract (n=524). Long-term aspirin use vs. No antithrombotic drugs or aspirin without cardiac surgery was evaluated on Bleeding-related complications (subconjunctival hemorrhage and hyphema) (p=> 0.05). Long-term aspirin use after PCI did not significantly increase the risk of bleeding-related complications during or after cataract phacoemulsification compared to controls (P>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: